AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9165564
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 1500 mg orally
Trial: 9165564
Drug: Ganciclovir 5
RxNorm normalized name: ganciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 5 mg/kg intravenously
Trial: 1350482
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg daily
Trial: 1350482
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg daily
Trial: 1350482
Drug: Carvedilol 6.25
RxNorm normalized name: carvedilol 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25 mg daily
Trial: 4001280
Drug: Desimipramine (DMI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desimipramine (DMI) 25 mg
Trial: 4001280
Drug: Desimipramine (DMI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desimipramine (DMI) 15 mg
Trial: 29197219
Drug: 0.05 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg/day of somatropin
Trial: 26935819
Drug: Sarolaner (Simparica™)
RxNorm normalized name: sarolaner Chewable Tablet [Simparica]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarolaner (Simparica™) at a minimum dose of 2 mg/kg
Trial: 25355697
Drug: Monthly or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly or bimonthly standard 3-day treatment regimens of dihydroartemisinin-piperaquine
Trial: 25355697
Drug: Monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dosing regimen based on the final model
Trial: 20888520
Drug: Testosterone transdermal
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone transdermal patch (T group, n = 24)
Trial: 12744768
Drug: Linezolid (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (intravenous followed by optional oral)
Trial: 12744768
Drug: Vancomycin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (intravenous only)
Trial: 12201213
Drug: Antithyroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid treatment (Group 1)
Trial: 7056011
Drug: Oral metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metaproterenol for four weeks
Trial: 7056011
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline for four weeks
Trial: 26924470
Drug: eOIT (egg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eOIT (egg oral immunotherapy)
Trial: 3266277
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) treatment
Trial: 22085872
Drug: Enalapril-FA tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-FA tablet (10 mg enalapril combined with 0.8 mg of FA, high FA group)
Trial: 22085872
Drug: Enalapril-FA tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-FA tablet (10 mg enalapril combined with 0.4 mg of FA, low FA group)
Trial: 19640950
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg anthocyanins twice daily for 12 weeks
Trial: 15619106
Drug: 1.74% THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.74% THC (low dose)
Trial: 15619106
Drug: 2.93% THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.93% THC (high dose)
Trial: 9482769
Drug: Quercetin-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin-containing supplement (1.0 g quercetin/d)
Trial: 8023779
Drug: Fluvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin, 20 mg/day for 6 weeks
Trial: 8023779
Drug: Fluvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin + niacin (titrated to a maximum of 3 g/day for a further 9 weeks)
Trial: 1097198
Drug: clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: clobetasol propionate cream 0.05%
Trial: 24341333
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) group
Trial: 20536470
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered Tbeta4 (0.03%)
Trial: 17993603
Drug: beta‐adrenergic blockade‐intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐adrenergic blockade‐intravenous propranolol (0.2 mg/kg)
Trial: 17993603
Drug: parasympathetic blockade‐intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parasympathetic blockade‐intravenous atropine (0.04 mg/kg)
Trial: 16368440
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) chemotherapy (paclitaxel 135 mg/m² IV over 24 h, cisplatin 100 mg/m² IP day 2, paclitaxel 60 mg/m² IP day 8) every 21 days for six cycles
Trial: 16368440
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) chemotherapy (alternate regimen for patients unable to receive IP therapy)
Trial: 12744096
Drug: Rubber band
RxNorm normalized name: CLOSURE,RUBBER BAND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubber band ligation + local anaesthetic injection (n = 70)
Trial: 8421077
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg continuous sc GHRH 1-44 infusion daily for 14 days
Trial: 8421077
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg continuous sc GHRH 1-44 infusion daily for 14 days
Trial: 8043977
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline measurements before treatment)
Trial: 2684916
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy (thrombolysis or coronary angioplasty or both)
Trial: 27852617
Drug: Long-chain n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain n-3 PUFA (3 g fish oil/d)
Trial: 27852617
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g safflower oil/d)
Trial: 21467302
Drug: Continuous iv
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv infusion of combined GHRH/GHRP‐2 during pharmacological estradiol (E(2); women) or testosterone (T; men) supplementation
Trial: 21467302
Drug: Continuous iv
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv infusion of combined GHRH/GHRP‐2
Trial: 7557823
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg) every 8 hours for three days
Trial: 1959004
Drug: Oxerutins (Paroven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxerutins (Paroven 500 mg twice daily)
Trial: 1959004
Drug: Both oxerutins
RxNorm normalized name: oxerutins
DrugBank: Oxerutins (DB15826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oxerutins and placebo (compliance with tablets and stockings)
Trial: 26573188
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 mg/day, oral)
Trial: 26573188
Drug: Adefovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir (10 mg/day, oral)
Trial: 23102599
Drug: High titer
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Trial: 23102599
Drug: Low titer
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Trial: 19055285
Drug: Bilateral Yongquan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral Yongquan (KI 1) application with Biyankang Tablet, once each night
Trial: 12591005
Drug: Borage oil
RxNorm normalized name: Borage oil
DrugBank: Borage oil (DB11238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil 3000 mg daily
Trial: 12591005
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil 3000 mg daily
Trial: 12591005
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil 1500 mg and borage oil 1500 mg daily
Trial: 11045840
Drug: Dietary counseling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counseling plus 628 +/- 254 mL of an energy supplement rich in fat (31% of energy) and linoleic acid (16% of energy) for 3 months
Trial: 1462745
Drug: Selective intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective intestinal decontamination (3 oral nonabsorbable antibiotics: Neomycin 1 gr, Colistin 1.500.000 U, Nystatin 1.000.000 U every 6 hours for first 74 patients; Norfloxacin 400 mg BID for following patients) for at least 5 days
Trial: 6239538
Drug: Low-dose chlorozotocin
RxNorm normalized name: chlorozotocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose chlorozotocin (120 mg/m2 if untreated, 100 mg/m2 if treated)
Trial: 6239538
Drug: High-dose chlorozotocin
RxNorm normalized name: chlorozotocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chlorozotocin (200 mg/m2 if untreated, 175 mg/m2 if treated)
Trial: 6239538
Drug: Low-dose and
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose and high-dose chlorozotocin
Trial: 6239538
Drug: High-dose chlorozotocin
RxNorm normalized name: chlorozotocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chlorozotocin
Trial: 30187978
Drug: Varenicline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5 mg for 1 week, then 1 mg for 11 weeks, twice daily)
Trial: 30187978
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical unlabelled tablets for 12 weeks)
Trial: 26242048
Drug: Qilin Pills
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills (6 g, tid) combined with clomiphene (50 mg, qd)
Trial: 26242048
Drug: Clomiphene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene (50 mg, qd) alone
Trial: 23482340
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (methotrexate injection alone)
Trial: 23482340
Drug: Conservative surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative surgery with post-operative methotrexate injection
Trial: 20586147
Drug: Polarized light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polarized light (PL) applied to neuropathic ulcers of diabetic foot twice daily for ten minutes for three months
Trial: 20586147
Drug: Antioxidants (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (60 mg hydrosoluble CoQ10, 100 mg alpha‐lipoic acid (ALA), and 200 mg vitamin E) used in two daily doses for three months
Trial: 3979007
Drug: Terbutaline (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.075 mg/kg three times a day)
Trial: 3979007
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (10 mg/kg twice a day)
Trial: 29708281
Drug: OBE022 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE022 (single ascending doses of 10, 30, 100, 300, 1000 or 1300 mg; multiple ascending doses of 100, 300 or 1000 mg day-1 for 7 days)
Trial: 24708640
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg) and magnesium (200 mg)
Trial: 12893153
Drug: Intra-articular Hyalgan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Hyalgan injections
Trial: 19276493
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg bolus dose followed by 75 mg once daily)
Trial: 16822130
Drug: Sequential effects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential effects in the Simon task
Trial: 12738811
Drug: SC‐51 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC‐51 (200 mg)
Trial: 15897698
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg once daily for 10 days
Trial: 10023111
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg lysine-acetylsalicylic acid i.v.
Trial: 10023111
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ergotamine s.c.
Trial: 7478833
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone phosphate 0.6 mg/kg/d (dexamethasone base 0.5 mg/kg/d)
Trial: 7049957
Drug: Erythromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (2 X 1 g daily per os)
Trial: 7049957
Drug: Amoxicillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (3 X 0.75 g daily per os)
Trial: 31134323
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (60 mg/m2)
Trial: 31134323
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine (25 mg/m2)
Trial: 31134323
Drug: Population pharmacokinetic
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population pharmacokinetic analysis (oral: n=222; intravenous: n=111)
Trial: 31134323
Drug: Reference European
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference European data set (oral: 80 mg/m2; intravenous: 30 mg/m2)
Trial: 22386472
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ABT-894 twice daily
Trial: 22386472
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ABT-894 twice daily
Trial: 22386472
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ABT-894 twice daily
Trial: 22386472
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg ABT-894 twice daily
Trial: 22386472
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg duloxetine once per day (Study 1)
Trial: 20201945
Drug: Pegylated Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Escherichia Coli Asparaginase (Peg‐ASP) 1000 units/m(2) with concurrent heparin prophylaxis
Trial: 15569860
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg
Trial: 12101076
Drug: Early dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early dexamethasone therapy
Trial: 10189536
Drug: rhIGF‐I at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I at a dose of 40/40 micrograms/kg
Trial: 10189536
Drug: rhIGF‐I at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I at a dose of 80/40 micrograms/kg
Trial: 10189536
Drug: rhIGF‐I at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I at a dose of 80/60 micrograms/kg
Trial: 10189536
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin therapy alone (placebo)
Trial: 10189536
Drug: rhIGF‐I/insulin cotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I/insulin cotherapy
Trial: 10189536
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of rhIGF‐I
Trial: 2271083
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (low-dose azathioprine, cyclosporin, methylprednisolone) continued (group A)
Trial: 27492741
Drug: Repetitive intracutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive intracutaneous injections with local anesthetics and steroids
Trial: 21899566
Drug: 24% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% EDTA gel (30 min)
Trial: 21899566
Drug: 2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHX gel (30 min)
Trial: 19014354
Drug: Desferroxamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferroxamine infusion for 8 hours
Trial: 19014354
Drug: Desferroxamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferroxamine infusion
Trial: 15343531
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia plus femoral nerve block (FNB) with 30 mL of 0.5% bupivacaine with epinephrine 1:200,000
Trial: 15343531
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia plus femoral nerve block (FNB) with 30 mL of preservative-free saline
Trial: 11451621
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days followed by chlormadinone acetate for 5 days
Trial: 9511844
Drug: Geriatric Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric Oral Health Assessment Index (GOHAI)
Trial: 9511844
Drug: Self-reported need
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported need for dental treatment
Trial: 7872725
Drug: CA 19.9
RxNorm normalized name: CA 19.9 - Carbohydrate antigen 19.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 19.9 > 37 U/ml
Trial: 7872725
Drug: CEA >
RxNorm normalized name: Carcinoembryonic Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEA > 5 ng/ml
Trial: 27185699
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg (P150)
Trial: 27185699
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg (P75)
Trial: 27185699
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg (D5)
Trial: 19531931
Drug: ProSorb-D 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProSorb-D 12.5 mg
Trial: 19531931
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 50 mg tablet
Trial: 15967914
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate cream, 40-g/d dosage
Trial: 15967914
Drug: Oral corticosteroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids, 0.5 or 1.0 mg/kg per day depending on extent of BP
Trial: 1902410
Drug: ponalrestat (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ponalrestat (two 300 mg tablets daily)
Trial: 31189759
Drug: Lipid-modifying therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modifying therapy (LT) level I with low HDL-C (＜40 mg/dL for men; ＜50 mg/dL for women)
Trial: 31189759
Drug: Lipid-modifying therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modifying therapy (LT) level II with high HDL-C (≥ 40 mg/dL for men; ≥ 50 mg/dL for women)
Trial: 31189759
Drug: Lipid-modifying therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modifying therapy (LT) level III with high HDL-C and low triglycerides (＜150 mg/dL)
Trial: 31189759
Drug: No lipid-modifying
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-modifying therapy (LT) prescribed (level 0)
Trial: 31189759
Drug: Lipid-modifying therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modifying therapy (LT) level I
Trial: 31189759
Drug: Lipid-modifying therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modifying therapy (LT) level II
Trial: 31189759
Drug: Lipid-modifying therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modifying therapy (LT) level III
Trial: 29088237
Drug: Current weekend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current weekend allied health service (including physical therapy, occupational therapy, speech therapy, dietetics, social work, and allied health assistant services)